Inactivated coxsackievirus A10 experimental vaccines protect mice against lethal viral challenge

Vaccine

Volumn 34, Issue 41, 2016, Pages 5005-5012

  Shen, Chaoyun ^a   Liu, Qingwei ^a   Zhou, Yu ^a   Ku, Zhiqiang ^a   Wang, Lili ^a   Lan, Ke ^a   Ye, Xiaohua ^a   Huang, Zhong ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

Author keywords

Beta propiolactone; Coxsackievirus A10; In vivo protection; Inactivated vaccine; Neutralizing antibody

Indexed keywords

COXSACKIEVIRUS A10 INACTIVATED VACCINE; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; PROPIOLACTONE; PROTEIN VP1; PROTEIN VP2; PROTEIN VP3; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS ANTIBODY;

ACTIVE IMMUNIZATION; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; COXSACKIEVIRUS A10 INFECTION; DRUG EFFICACY; ENTEROVIRUS INFECTION; FEMALE; MALE; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; VIRUS IMMUNITY; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; BLOOD; ENTEROVIRUS; HAND FOOT AND MOUTH DISEASE; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; SERODIAGNOSIS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ENTEROVIRUS; FEMALE; HAND, FOOT AND MOUTH DISEASE; IMMUNIZATION, PASSIVE; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; NEUTRALIZATION TESTS; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 84990063425     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.08.033     Document Type: Article

References (49)

1. [1] Chan, L.G., Parashar, U.D., Lye, M.S., Ong, F.G.L., Zaki, S.R., Alexander, J.P., et al. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. Clin Infect Dis 31 (2000), 678–683.
2. [2] Ang, L.W., Koh, B.K.W., Chan, K.P., Chua, L.T., James, L., Goh, K.T., Epidemiology and control of hand, foot and mouth disease in Singapore, 2001–2007. Ann Acad Med Singapore 38 (2009), 106–112.
3. [3] Zhang, Y., Zhu, Z., Yang, W., Ren, J., Tan, X., Wang, Y., et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J, 7, 2010, 94.
4. [4] Mauleekoonphairoj, J., Vongpunsawad, S., Puenpa, J., Korkong, S., Poovorawan, Y., Complete genome sequence analysis of enterovirus 71 isolated from children with hand, foot, and mouth disease in Thailand, 2012–2014. Virus Genes 51 (2015), 290–293.
5. [5] Wong, S.S.Y., Yip, C.C.Y., Lau, S.K.P., Yuen, K.Y., Human enterovirus 71 and hand, foot and mouth disease. Epidemiol Infect 138 (2010), 1071–1089.
6. [6] Xing, W., Liao, Q., Viboud, C., Zhang, J., Sun, J., Wu, J.T., et al. Hand, foot, and mouth disease in China, 2008–12: an epidemiological study. Lancet Infect Dis 14 (2014), 308–318.
7. [7] He, Y.Q., Chen, L., Xu, W.B., Yang, H., Wang, H.Z., Zong, W.P., et al. Emergence, circulation, and spatiotemporal phylogenetic analysis of coxsackievirus a6- and coxsackievirus a10-associated hand, foot, and mouth disease infections from 2008 to 2012 in Shenzhen, China. J Clin Microbiol 51 (2013), 3560–3566.
8. [8] Lu, Q.B., Zhang, X.A., Wo, Y., Xu, H.M., Li, X.J., Wang, X.J., et al. Circulation of Coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009–2011. PLoS ONE, 7, 2012, e52073.
9. [9] Itagaki, A., Kamahora, T., Kurimura, T., Isolation and characterization of a cold-sensitive strain of Coxsackievirus A10. J Gen Virol 68 (1987), 1191–1194.
10. [10] Tian, H., Zhang, Y., Sun, Q., Zhu, S., Li, X., Pan, Z., et al. Prevalence of multiple enteroviruses associated with hand, foot, and mouth disease in Shijiazhuang City, Hebei province, China: outbreaks of coxsackieviruses a10 and b3. PLoS ONE, 9, 2014, e84233.
11. [11] Yang, Q., Ding, J., Cao, J., Huang, Q., Hong, C., Yang, B., Epidemiological and etiological characteristics of hand, foot, and mouth disease in Wuhan, China from 2012 to 2013: outbreaks of coxsackieviruses A10. J Med Virol 87 (2015), 954–960.
12. [12] Mirand, A., Henquell, C., Archimbaud, C., Ughetto, S., Antona, D., Bailly, J.L., et al. Outbreak of hand, foot and mouth disease/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: a large citywide, prospective observational study. Clin Microbiol Infec 18 (2012), E110–E118.
13. [13] Davia, J.L., Bel, P.H., Ninet, V.Z., Bracho, M.A., Gonzalez-Candelas, F., Salazar, A., et al. Onychomadesis outbreak in Valencia, Spain associated with hand, foot, and mouth disease caused by enteroviruses. Pediatr Dermatol 28 (2011), 1–5.
14. [14] Okada, H., Wada, M., Sato, H., Yamaguchi, Y., Tanji, H., Kurokawa, K., et al. Neuromyelitis optica preceded by hyperCKemia and a possible association with coxsackie virus group A10 infection. Internal Med 52 (2013), 2665–2668.
15. [15] Fuschino, M.E., Lamson, D.M., Rush, K., Carbone, L.S., Taff, M.L., Hua, Z., et al. Detection of coxsackievirus A10 in multiple tissues of a fatal infant sepsis case. J Clin Virol 53 (2012), 259–261.
16. [16] Embil, J.A., Vanrooye, C.E., Nagler, F.P., Coxsackie A10 virus infection among infectious hepatitis contacts. Can Med Assoc J, 93, 1965, 740.
17. [17] Blomqvist, S., Klemola, P., Kaijalainen, S., Paananen, A., Simonen, M.L., Vuorinen, T., et al. Co-circulation of coxsackieviruses A6 and A10 in hand, foot and mouth disease outbreak in Finland. J Clin Virol 48 (2010), 49–54.
18. [18] Puenpa, J., Mauleekoonphairoj, J., Linsuwanon, P., Suwannakarn, K., Chieochansin, T., Korkong, S., et al. Prevalence and characterization of enterovirus infections among pediatric patients with hand foot mouth disease, herpangina and influenza like illness in Thailand, 2012. PLoS ONE, 9, 2014.
19. [19] Gopalkrishna, V., Patil, P.R., Patil, G.P., Chitambar, S.D., Circulation of multiple enterovirus serotypes causing hand, foot and mouth disease in India. J Med Microbiol 61 (2012), 420–425.
20. [20] Lu, Q.B., Zhang, X.A., Wo, Y., Xu, H.M., Li, X.J., Wang, X.J., et al. Circulation of Coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009–2011. PLoS ONE, 7, 2012.
21. [21] Guan, H.Y., Wang, J., Wang, C.R., Yang, M.J., Liu, L.Z., Yang, G.L., et al. Etiology of multiple non-EV71 and non-CVA16 enteroviruses associated with hand, foot and mouth disease in Jinan, China, 2009–June 2013. PLoS ONE, 10, 2015.
22. [22] He, Y.Q., Chen, L., Xu, W.B., Yang, H., Wang, H.Z., Zong, W.P., et al. Emergence, circulation, and spatiotemporal phylogenetic analysis of Coxsackievirus A6-and Coxsackievirus A10-associated hand, foot, and mouth disease infections from 2008 to 2012 in Shenzhen, China. J Clin Microbiol 51 (2013), 3560–3566.
23. [23] Heinsbroek, E., Ruitenberg, E.J., The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox. Vaccine 28 (2010), 3778–3783.
24. [24] Zhu, F.C., Meng, F.Y., Li, J.X., Li, X.L., Mao, Q.Y., Tao, H., et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 381 (2013), 2024–2032.
25. [25] Mao, Q.Y., Wang, Y., Bian, L., Xu, M., Liang, Z., EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines, 1–8, 2016.
26. [26] Zhu, F., Xu, W., Xia, J., Liang, Z., Liu, Y., Zhang, X., et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 370 (2014), 818–828.
27. [27] Liu, Q., Yan, K., Feng, Y., Huang, X., Ku, Z., Cai, Y., et al. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine 30 (2012), 6642–6648.
28. [28] Ku, Z., Liu, Q., Ye, X., Cai, Y., Wang, X., Shi, J., et al. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine 32 (2014), 4296–4303.
29. [29] Zhang, C., Liu, Q., Ku, Z., Hu, Y., Ye, X., Zhang, Y., et al. Coxsackievirus A16-like particles produced in Pichia pastoris elicit high-titer neutralizing antibodies and confer protection against lethal viral challenge in mice. Antiviral Res 129 (2016), 47–51.
30. [30] Ku, Z., Ye, X., Huang, X., Cai, Y., Liu, Q., Li, Y., et al. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS ONE, 8, 2013, e57601.
31. [31] Cai, Y., Liu, Q., Huang, X., Li, D., Ku, Z., Zhang, Y., et al. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine 31 (2013), 2215–2221.
32. [32] Yang, E., Cheng, C., Zhang, Y., Wang, J., Che, Y., Pu, J., et al. Comparative study of the immunogenicity in mice and monkeys of an inactivated CA16 vaccine made from a human diploid cell line. Hum Vaccin Immunother 10 (2014), 1266–1273.
33. [33] Liu, C.C., Guo, M.S., Wu, S.R., Lin, H.Y., Yang, Y.T., Liu, W.C., et al. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles. Antiviral Res 129 (2016), 58–66.
34. [34] Liu, Q., Ku, Z., Cai, Y., Sun, B., Leng, Q., Huang, Z., Detection, characterization and quantitation of coxsackievirus A16 using polyclonal antibodies against recombinant capsid subunit proteins. J Virol Methods 173 (2011), 115–120.
35. [35] Liu, Q., Huang, X., Ku, Z., Wang, T., Liu, F., Cai, Y., et al. Characterization of enterovirus 71 capsids using subunit protein-specific polyclonal antibodies. J Virol Methods 187 (2013), 127–131.
36. [36] Stanic, M., A simplification of the estimation of the 50 percent endpoints according to the Reed and Muench method. Pathol Microbiol (Basel) 26 (1963), 298–302.
37. [37] Cai, Y., Ku, Z., Liu, Q., Leng, Q., Huang, Z., A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses. Vaccine 32 (2014), 2406–2412.
38. [38] Ye, X., Ku, Z., Liu, Q., Wang, X., Shi, J., Zhang, Y., et al. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms. J Virol 88 (2014), 72–81.
39. [39] Perrin, P., Morgeaux, S., Inactivation of DNA by beta-propiolactone. Biologicals 23 (1995), 207–211.
40. [40] Chong, P., Guo, M.S., Lin, F.H.Y., Hsiao, K.N., Weng, S.Y., Chou, A.H., et al. Immunological and biochemical characterization of Coxsackie virus A16 viral particles. PLoS ONE, 7, 2012.
41. [41] Murdin, A.D., Barreto, L., Plotkin, S., Inactivated poliovirus vaccine: past and present experience. Vaccine 14 (1996), 735–746.
42. [42] Vlecken, D.H., Pelgrim, R.P., Ruminski, S., Bakker, W.A., van der Pol, L.A., Comparison of initial feasibility of host cell lines for viral vaccine production. J Virol Methods 193 (2013), 28–41.
43. [43] Kalbfuss, B., Wolff, M., Morenweiser, R., Reichl, U., Purification of cell culture-derived human influenza A virus by size-exclusion and anion-exchange chromatography. Biotechnol Bioeng 96 (2007), 932–944.
44. [44] Govorkova, E.A., Murti, G., Meignier, B., de Taisne, C., Webster, R.G., African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses. J Virol 70 (1996), 5519–5524.
45. [45] Basavappa, R., Syed, R., Flore, O., Icenogle, J.P., Filman, D.J., Hogle, J.M., Role and mechanism of the maturation cleavage of VP0 in poliovirus assembly: structure of the empty capsid assembly intermediate at 2.9 A resolution. Protein Sci 3 (1994), 1651–1669.
46. [46] Chong, P., Liu, C.C., Chow, Y.H., Chou, A.H., Klein, M., Review of enterovirus 71 vaccines. Clin Infect Dis 60 (2015), 797–803.
47. [47] Liu, C.C., Guo, M.S., Lin, F.H., Hsiao, K.N., Chang, K.H., Chou, A.H., et al. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS ONE, 6, 2011, e20005.
48. [48] Liu, C.C., Lian, W.C., Butler, M., Wu, S.C., High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine 25 (2007), 19–24.
49. [49] Wu, C.Y., Lin, Y.W., Kuo, C.H., Liu, W.H., Tai, H.F., Pan, C.H., et al. Inactivated enterovirus 71 vaccine produced by 200-L scale serum-free microcarrier bioreactor system provides cross-protective efficacy in human SCARB2 transgenic mouse. PLoS ONE, 10, 2015.